Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Profit After Tax (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Profit After Tax for 6 consecutive years, with -$54.9 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 27.78% to -$54.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$276.5 million through Dec 2025, up 18.13% year-over-year, with the annual reading at -$276.5 million for FY2025, 18.13% up from the prior year.
  • Profit After Tax for Q4 2025 was -$54.9 million at Relay Therapeutics, up from -$74.1 million in the prior quarter.
  • The five-year high for Profit After Tax was -$42.2 million in Q1 2021, with the low at -$193.4 million in Q2 2021.
  • Average Profit After Tax over 5 years is -$80.5 million, with a median of -$76.4 million recorded in 2022.
  • The sharpest move saw Profit After Tax plummeted 623.69% in 2021, then soared 60.3% in 2022.
  • Over 5 years, Profit After Tax stood at -$67.5 million in 2021, then decreased by 0.07% to -$67.5 million in 2022, then dropped by 23.69% to -$83.5 million in 2023, then increased by 8.97% to -$76.0 million in 2024, then increased by 27.78% to -$54.9 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$54.9 million, -$74.1 million, and -$70.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.